Arteris VP Paul Alpern sells $3,317 in common stock

Published 07/03/2025, 23:08
Arteris VP Paul Alpern sells $3,317 in common stock

Paul L. Alpern, Vice President and General Counsel of Arteris , Inc. (NASDAQ:AIP), has recently sold shares of the company. According to a filing with the Securities and Exchange Commission, Alpern sold 406 shares of Arteris common stock on March 6, 2025. The shares were sold at a price of $8.17 each, totaling approximately $3,317. The stock has since declined to $7.89, marking a significant 13.4% drop over the past week. InvestingPro data shows the company maintains impressive gross profit margins of nearly 90%.

Following this transaction, Alpern retains ownership of 90,204 shares. The sale was executed under a 10b5-1 trading plan, which Alpern adopted on May 8, 2024. This type of plan allows insiders of publicly traded corporations to set up a predetermined schedule for selling stocks they own. Despite recent price weakness, analysts maintain optimistic price targets ranging from $11 to $16 per share. Get deeper insights into AIP’s valuation and 7 additional key ProTips with InvestingPro’s comprehensive research report.

In other recent news, Arteris, Inc. has seen notable developments impacting its financial outlook and market perception. Jefferies analyst Blayne Curtis raised the company’s price target to $11 from $7, maintaining a Hold rating, citing Arteris’ progress in the microcontroller unit market, which includes a significant win at IFX. The introduction of the FlexGen solution is expected to increase the average selling price per license by 30%, potentially accelerating the company’s path to breakeven by 2025. Despite these advancements, Jefferies remains cautious, awaiting more evidence of improved execution in MCU and FlexGen license sales.

Meanwhile, Northland analysts have increased their price target for Arteris to $16 from $14, keeping an Outperform rating, following the successful launch of the new FlexGen product. Arteris reported revenue that met expectations, with bookings of approximately $33.6 million and a book-to-bill ratio of 2.2:1. The FlexNoC 5 product has also been successful, accounting for a significant portion of interconnect licenses. Northland’s increased price target reflects the anticipated positive impact of FlexGen on Arteris’ financial performance, with 13 customers currently evaluating the product.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.